Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Support Care Cancer ; 25(4): 1087-1096, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28013416

RESUMO

PURPOSE: Cancer survivors often report posttraumatic growth (PTG). The aims of this study were to assess the presence of PTG in Italian long-term disease-free cancer survivors (LCS) and to explore the association between the dimensions of PTG and clinical, demographic variables, various agents of perceived social support and psychological distress. METHODS: Five hundred forty LCS were assessed with Posttraumatic Growth Inventory (PTGI), Multidimensional Scale of Perceived Social Support (MSPSS), Zung Self-Rating Depression Scale, and State-Trait Anxiety Inventory-Y (STAI-Y). RESULTS: Mean age was 57.08 years, mean survival was 11.04 years (range 5-32), and the most common cancer diagnosis was breast cancer (56.9%). The PTGI average total score was higher in more educated LCS, in those employed, in LCS with longer time from diagnosis, and in those with no comorbidities. In this study, PTG was not found correlated with distress, but it correlated with perceived social support, age, education, and employment. CONCLUSIONS: The absence of a correlation between PTG and psychological distress and the low levels of PTG found let us question the importance of talking about PTG when working as psychotherapists with LCS. It may be suggested that the need of finding benefit and PTG in LCS has been overcome by other experiences or worries happened after the cancer, and LCS may not focus anymore on positive changes occurred. The relevance of work and of perceived social support as linked to PTG stresses the need to protect the LCS's relationship with work and to promote and sustain their social network, and this can help them to experience sharing and closeness to others.


Assuntos
Adaptação Psicológica , Neoplasias/psicologia , Sobreviventes/psicologia , Adulto , Idoso , Ansiedade , Neoplasias da Mama/psicologia , Feminino , Humanos , Pessoa de Meia-Idade , Percepção , Apoio Social
2.
Support Care Cancer ; 23(9): 2663-8, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25646617

RESUMO

PURPOSE: Since long-term survivorship is now a reality for an increasingly number of people with a history of cancer, understanding their quality of life (QoL) can inform health care policy as well as help supporting individual patients. This study was aimed to quantify QoL of this specific population in comparison with data provided for both the general population and cancer patients and to assess QoL association with several sociodemographic, clinical, and psychological variables. METHODS: Three hundred fourteen Italian long-term cancer survivors (people who have been free from cancer and cancer treatments for at least 5 years) completed a battery of questionnaires including the SF12 for QoL assessment. RESULTS: Both physical and mental functioning were higher than those among Italian cancer patients but lower than those of the Italian general population (p < .001). Poorer QoL (physical and mental functioning) was associated more often with psychological conditions (as anxiety and depression) than with sociodemographic and cancer-related variables. CONCLUSIONS: These data support an ongoing specific interest in the QoL of long-term cancer survivors and suggest the need for further study of multidimensional functioning in this population.


Assuntos
Neoplasias/fisiopatologia , Neoplasias/psicologia , Sobreviventes/psicologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Psicometria/métodos , Qualidade de Vida/psicologia , Inquéritos e Questionários
3.
Tumori ; 101 Suppl 1: S14-8, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-27096266

RESUMO

The National Cancer Institute of Bari (Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS) has been involved since the conception of the project of the Italian Ministry for Health aimed to validate the applicability of the Organisation of European Cancer Institutes (OECI) accreditation and designation (A&D) model to the Network of Italian Cancer Centers, IRCCS, of Alleanza Contro il Cancro. The self-assessment phase of the Institute started in September 2013 and ended in June 2014. All documents and tools were transferred to the OECI A&D Board in June 2014 and a 2-day peer review visit was conducted in October 2014 by an international qualified audit team. The Institute received its final designation and certification in June 2015. The OECI A&D Board, in its final report, came to the conclusion that Istituto Tumori "Giovanni Paolo II" of Bari has a strong research component with some essential elements of comprehensive cancer care still under development; the lack of a system for using outcome data for the strategic management approach to decision-making and missing a regular internal audit system eventually helping further quality improvement were reported as examples of areas with opportunities for improvement. The OECI A&D process represented a great opportunity for the cancer center to benchmark the quality of its performance according to standard parameters in comparison with other international centers and to further develop a participatory group identity. The common goal of accreditation was real and participatory with long-lasting positive effects. We agree with the OECI comments about the next areas of work in which the Institute could produce future further efforts: the use of its powerful IT system as a means for outcome analysis and empowerment projects for its cancer patients.


Assuntos
Acreditação , Benchmarking , Institutos de Câncer/normas , Neoplasias , Qualidade da Assistência à Saúde , Pesquisa Biomédica , Certificação , Ensaios Clínicos como Assunto , Procedimentos Clínicos/normas , Europa (Continente) , Humanos , Comunicação Interdisciplinar , Itália , Neoplasias/prevenção & controle , Neoplasias/terapia , Papel do Profissional de Enfermagem , Cuidados Paliativos/normas , Revisão por Pares , Guias de Prática Clínica como Assunto , Prevenção Primária/normas , Gestão de Riscos
4.
Front Psychol ; 5: 1342, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25477853

RESUMO

INTRODUCTION: Although research has shown that many cancer patients report positive life changes following cancer diagnosis, there are few data in the literature related to PTG in caregivers of cancer patients. However, the few studies available have shown that this kind of positive changes can also be experienced by family members. The aims of this study were to explore PTG in caregivers of cancer patients and to investigate correlations between the Posttraumatic growth, psychological status and QoL of caregivers and those of patients, taking into account also clinical and socio-demographic aspects. METHODS: We enrolled 60 patient/caregiver pairs in the Department of Medical Oncology of the National Research Center "Giovanni Paolo II" in Bari. Both patients and caregivers were assessed using the following scales: Posttraumatic growth Inventory (PTGI); Hospital anxiety and depression scale; Short Form (36) Health Survey (SF-36); ECOG Performance Status. Clinical and socio-demographic data were collected. RESULTS: Caregivers showed significantly higher scores than patients in the dimension of "personal strength." Furthermore, we found a significantly close association between anxiety and depression of caregivers with those of patients. Younger caregivers were better than older ones in terms of physical activity, vitality, mental health, and social activities. Although the degree of relationship with the patient has no significant effect on the dependent variables of the study, it was found that caregivers with a degree of kinship more distant to the patient have less physical pain than the closest relatives. CONCLUSION: RESULTS of the present study show that caregivers of cancer patients may experience post-traumatic growth as the result of their caregiver role. It would be interesting to investigate in future research which factor may mediate the presence of post-traumatic growth.

5.
EJC Suppl ; 12(1): 54-64, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26217166

RESUMO

The population of cancer survivors has grown steadily over the past several decades. Surviving cancer, however, is not synonymous with a life free of problems related to the disease and its treatment. In this paper we provide a brief overview of selected physical and psychosocial health problems prevalent among cancer survivors, namely pain, fatigue, psychological distress and work participation. We also address issues surrounding self-management and e-Health interventions for cancer survivors, and programmes to encourage survivors to adopt healthier lifestyles. Finally, we discuss approaches to assessing health-related quality of life in cancer survivors, and the use of cancer registries in conducting psychosocial survivorship research. We highlight research and practice priorities in each of these areas. While the priorities vary per topic, common themes that emerged included: (1) Symptoms should not be viewed in isolation, but rather as part of a cluster of interrelated symptoms. This has implications for both understanding the aetiology of symptoms and for their treatment; (2) Psychosocial interventions need to be evidence-based, and where possible should be tailored to the needs of the individual cancer survivor. Relatively low cost interventions with self-management and e-Health elements may be appropriate for the majority of survivors, with resource intensive interventions being reserved for those most in need; (3) More effort should be devoted to disseminating and implementing interventions in practice, and to evaluating their cost-effectiveness; and (4) Greater attention should be paid to the needs of vulnerable and high-risk populations of survivors, including the socioeconomically disadvantaged and the elderly.

6.
Clin Biochem ; 47(3): 184-90, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24355694

RESUMO

BACKGROUND AND AIMS: Trans-hepatic arterial chemo-embolization is the most commonly used treatment for unresectable hepatocellular carcinoma. The prognostic impact of tumor biomarkers has not therefore been evaluated in this treatment. Imbalance between matrix metalloproteinase-2 and tissue inhibitor metalloproteinase-2 is considered to play an important role in extracellular matrix remodeling and degradation. Higher serum levels of MMP-2 have been shown to predict a poor prognosis and shorter overall survival in HCC after TACE. The objective of this study was to evaluate the serum levels of MMP-2 and TIMP-2 in HCC patients before and after TACE to evaluate their clinical significance and usefulness as prognostic biomarkers. METHODS: MMP-2 and TIMP-2 levels were measured by ELISA in 75 HCC patients and 30 healthy controls. Sera MMP-2 and TIMP-2 were correlated with clinico-pathological features. RESULTS: The mean serum MMP-2 and TIMP-2 levels of HCC patients before TACE were 1700±71ng/mL and 89±45ng/mL respectively, significantly higher than that of the control group: 771±60ng/mL (p<0.0001, t-test) and 25.7±20ng/mL respectively (p<0.0001, t-test). A significant decrease of MMP-2 levels after 1 and 3months compared to baseline time was observed (p<0.0001), while with TIMP-2 a gradual increase in serum before and after TACE (p<0.01) was detected. No significant correlation between serum MMP-2 levels and other clinico-pathological features was observed. Patients with serum MMP-2 >1500ng/mL (median value) had worse overall and recurrence-free survival compared with those with serum MMP-2 levels <1500ng/mL before treatment. CONCLUSION: Higher serum MMP-2 levels and MMP-2/TIMP-2 ratio could predict poor prognosis after TACE, suggesting prognostic role of these biomarkers in HCC.


Assuntos
Biomarcadores Tumorais/sangue , Carcinoma Hepatocelular , Quimioembolização Terapêutica , Neoplasias Hepáticas , Metaloproteinase 2 da Matriz/sangue , Inibidor Tecidual de Metaloproteinase-2/sangue , Idoso , Idoso de 80 Anos ou mais , Carcinoma Hepatocelular/sangue , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/terapia , Intervalo Livre de Doença , Feminino , Humanos , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/terapia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Taxa de Sobrevida
7.
Cancer ; 119 Suppl 11: 2083-5, 2013 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-23695918

RESUMO

The authors describe the rationale and background of the present supplement to Cancer intended to stimulate a dialogue among researchers from Europe and North America regarding important issues faced by cancer survivors. Through jointly written articles addressing various aspects of cancer survivorship, each manuscript reports on the similarities, disparities, and problems viewed from the point of view of each author's respective continent. The supplement is meant to create a springboard for increased collaboration and aid in the development of a shared care model to improve the quality of cancer care, both during and after the completion of primary treatment. We hope that this effort may represent a new model of international cooperation, which is fruitful not only for the field of scientific research but also for identifying and sharing new approaches to the care and management of cancer survivorship issues, ultimately bringing improvements to quality of life of the growing population of cancer survivors.


Assuntos
Neoplasias/psicologia , Neoplasias/reabilitação , Humanos , Cooperação Internacional , Taxa de Sobrevida , Sobreviventes/psicologia
8.
Cancer ; 119 Suppl 11: 2094-108, 2013 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-23695922

RESUMO

The growing number of cancer survivors worldwide has led to of the emergence of diverse survivorship movements in the United States and Europe. Understanding the evolution of cancer survivorship within the context of different political and health care systems is important for identifying the future steps that need to be taken and collaborations needed to promote research among and enhance the care of those living after cancer. The authors first review the history of survivorship internationally and important related events in both the United States and Europe. Lessons learned from survivorship research are then broadly discussed, followed by examination of the infrastructure needed to sustain and advance this work, including platforms for research, assessment tools, and vehicles for the dissemination of findings. Future perspectives concern the identification of collaborative opportunities for investigators in Europe and the United States to accelerate the pace of survivorship science going forward.


Assuntos
Neoplasias/mortalidade , Pesquisa Biomédica , Atenção à Saúde , Europa (Continente)/epidemiologia , União Europeia , Humanos , Taxa de Sobrevida/tendências , Sobreviventes , Estados Unidos/epidemiologia
9.
Radiology ; 267(2): 627-37, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23249572

RESUMO

PURPOSE: To evaluate the feasibility, safety, and effectiveness of combining segmental pulmonary arterial chemoembolization (SPACE) and percutaneous radiofrequency (RF) ablation in patients with unresectable lung neoplasms or patients with resectable neoplasms who refused surgery and to compare the local tumor progression (LTP) rate with that in previous studies of RF ablation alone. MATERIALS AND METHODS: After institutional review board approval and informed consent, 17 patients with primary and metastatic lung cancer were enrolled in this prospective study. Between January 2008 and February 2011, 20 nodules (median diameter, 3.0 cm; range, 2.0-5.0 cm) were treated during 19 sessions. Antineoplastic agents loaded on 50-100-µm microspheres were selectively infused into specific pulmonary arteries. Percutaneous computed tomography (CT)-guided RF ablation of lung nodules was performed 48 hours after SPACE. Follow-up consisted of enhanced CT 48 hours after combination treatment was completed, after 30 days, and every 3 months thereafter. Fluorine 18 fluorodeoxyglucose positron emission tomography was performed 3 months after combination therapy and then every 6 months. The t test was used to compare groups. RESULTS: Technical success was achieved in 100% of cases. Ventilation-lung single photon emission computed tomography showed a wide area without ventilation in the lung parenchyma treated with SPACE. The LTP rate was 21% (three of 14 nodules) in 3-5-cm-diameter tumors and 0% (zero of six nodules) in tumors of 3 cm or smaller in diameter. Complete response was achieved in 65% (11 of 17) of patients at minimum follow-up of 6 months. Overall, treatment was well tolerated. Major complications were pneumothorax in five of 19 sessions (26%) and one bronchopleural fistula (one of 19, 5%). No treatment-related changes in general lung function were noted. CONCLUSION: Combination therapy with RF ablation after SPACE to treat unresectable lung tumors is technically feasible, safe, and effective and may represent an advantage over RF ablation alone.


Assuntos
Antineoplásicos/administração & dosagem , Ablação por Cateter/métodos , Quimioembolização Terapêutica/métodos , Cisplatino/administração & dosagem , Doxorrubicina/administração & dosagem , Neoplasias Pulmonares/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Progressão da Doença , Estudos de Viabilidade , Feminino , Fluordesoxiglucose F18 , Humanos , Neoplasias Pulmonares/diagnóstico por imagem , Masculino , Microesferas , Pessoa de Meia-Idade , Tomografia por Emissão de Pósitrons , Estudos Prospectivos , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X , Resultado do Tratamento
11.
In Vivo ; 25(6): 895-901, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22021682

RESUMO

A functional polymorphism in the promoter region of the 5-hidroxytryptamine transporter gene (5-HTTLPR), alters its transcription. Short allele (SS) variation decreases the transcriptional efficacy of serotonin, causing psychiatric disorders, major depressive disorder (MDD) and major depression in response to stressful life events. The aim of this study was to determine the current understanding of the role of 5-HTTLPR polymorphism in the development of depressive episodes and its response to treatment. Twenty-five articles were identified from PubMed, utilizing the following keyword, 5-HTT transporter gene, polymorphism, depression, stressful condition, psychiatric disorder. All articles were read and notes were made regarding study participant, measures, data analysis and results, and were used to write this review. The distribution of the SS allele in patients is associated with an increased risk of MDD following exposure to stressful events of life. Additionally, this genetic variant is closely associated with several psychiatric conditions such as suicidal behaviour, psychoses, personality disorders, and aggressive-impulsive traits.


Assuntos
Antidepressivos de Segunda Geração/uso terapêutico , Transtorno Depressivo Maior/genética , Acontecimentos que Mudam a Vida , Transtornos Mentais/genética , Polimorfismo Genético , Proteínas da Membrana Plasmática de Transporte de Serotonina/genética , Transtorno Depressivo Maior/tratamento farmacológico , Humanos , Transtornos Mentais/tratamento farmacológico
12.
Tumori ; 97(3): 374-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21789019

RESUMO

AIMS AND BACKGROUND: The increasingly older population confronts oncologists with an imposing challenge: older cancer patients have specific healthcare needs both independent of and associated with the diagnosis of cancer. The aim of the present study is to examine whether elderly versus younger cancer patients have different needs with respect to attendance, treatment and information. METHODS AND STUDY DESIGN: This is an observational and cross-sectional study. Cancer patients aged 35 to 82 years were consecutively interviewed. The group was divided into two subgroups aged ≤65 and ≥66 years old. The Needs Evaluation Questionnaire (NEQ) was used to assess patients' needs and demographic variables were collected. Data analysis was carried out by means of cross-tabulation analyses and the chi-square test. RESULTS: The requests most frequently expressed by the older group concerned financial-insurance information (73.9%), the need to talk to people with the same illness (71.7%), the need to receive more comprehensible information from doctors and nurses (71.7%), and the need for a better dialogue with clinicians (69.6%). Few significant differences between the two age subgroups were found, with the exception of issues such as the need for intimacy and support. CONCLUSIONS: Elderly patients have informational and relational needs similar to those of younger patients. In fact, most of the whole sample flagged up the need for higher levels of satisfaction especially concerning a better dialogue with health staff, along with a new factor: the need to talk to people with the same illness.


Assuntos
Necessidades e Demandas de Serviços de Saúde , Cobertura do Seguro , Neoplasias , Satisfação do Paciente , Relações Profissional-Paciente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Distribuição de Qui-Quadrado , Estudos Transversais , Feminino , Humanos , Seguro Saúde , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários
13.
J Cancer Surviv ; 4(3): 284-9, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20652433

RESUMO

INTRODUCTION: Improvement in cancer survival rates have increased longevity but have also revealed physical and psycho-social sequelae of long-term survivorship and raised many questions regarding how to assess, treat, and prevent these survival-related problems. The United States, Australia, and some northern European Union countries have already started to address these issues. Italy still needs to take up this challenge, taking into account its specific social and cultural background that shapes a different survivorship scenario. METHODS: This brief report summarizes the concept of cancer survivorship and the response to this emerging public health issue in Italy. Two current nationwide research programs on long-term cancer survivorship and post-cancer pain are described to provide readers with a perspective of how Italy is seeking to increase the understanding of the needs and problems of cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: The results of these nationwide research programs will provide an evidence base for reforming the national care plans to address the needs of the growing number of Italian people with a history of cancer. It is hoped that this description of Italy's response to this public health challenge will offer some insight into how Italy is responding to the health and psychosocial needs of cancer survivors.


Assuntos
Neoplasias/mortalidade , Neoplasias/prevenção & controle , Padrões de Prática Médica , Pesquisa/tendências , Sobreviventes , Humanos , Itália/epidemiologia , Taxa de Sobrevida
14.
Support Care Cancer ; 18(3): 329-34, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19484487

RESUMO

GOALS OF WORK: Advanced colorectal cancer (CRC) has recently been treated with monoclonal antibodies, such as cetuximab. Skin toxicity is a peculiar side effect of cetuximab that may induce patients to interrupt therapy if it becomes serious. This study investigates the psychological and social sequelae of skin rash. MATERIALS AND METHODS: Patients affected by advanced CRC and treated with cetuximab-based therapy entered the trial. The following questionnaires were used: the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) to measure quality of life (QoL) and the Psychological Distress Inventory (PDI). A single item regarding social avoidance was added with a three-point Likert scale. Toxicity was assessed using the National Cancer Institute Criteria (NCI-2). MAIN RESULTS: Eighty patients were recruited; 41% presented psychological distress. As regards social avoidance, 53% of patients answered that they did not avoid going out at all. The rest of the sample answered that they "very much" (22%) or "somewhat" (25%) avoided going out. Psychological distress and social avoidance were not correlated to skin rash, but only to QoL. CONCLUSION: Skin rash was not found to impact patients' psychological status or social life. Two likely explanations for this finding were that (a) patients with advanced cancer consider skin rash as a part of the complex suffering caused by cancer and (b) patients are encouraged by oncologists to continue treatment because skin rash is indicative of response to therapy. This expectation brings hope and helps patients bear the drug-related side effects.


Assuntos
Anticorpos Monoclonais/efeitos adversos , Antineoplásicos/efeitos adversos , Ansiedade/psicologia , Neoplasias Colorretais/tratamento farmacológico , Toxidermias/psicologia , Qualidade de Vida/psicologia , Comportamento Social , Adulto , Idoso , Anticorpos Monoclonais Humanizados , Cetuximab , Toxidermias/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Inventário de Personalidade , Vigilância da População/métodos , Inquéritos e Questionários
15.
In Vivo ; 23(5): 813-20, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19779117

RESUMO

BACKGROUND: Radiofrequency thermal ablation (RFA) has been demonstrated to be useful for the treatment of liver neoplasms. The study aimed to evaluate the feasibility and safety of the combination of transarterial chemoembolization (TACE) and RFA, performed simultaneously to treat primary and secondary liver neoplasms. PATIENTS AND METHODS: From July 2006 to October 2007, 34 patients (21 with HCC and 13 with liver metastases) underwent 37 sessions of treatment. The schedule consisted of: induction TACE (with epirubicin, mitomycin C and lipiodol, or with doxorubicin/irinotecan loaded on microspheres), percutaneous RFA and second TACE. Monopolar RFA was used on 52 nodules, whereas the bipolar multiprobe technique was used in 6 cases. RESULTS: The treatment was well tolerated, with moderate hepatic and hematological toxicity. In total 51 nodules were evaluable for response, with technical success in 45/51 cases (88%). CONCLUSION: Combined TACE plus RFA is feasible and safe; the preliminary data make it a promising procedure with regard to efficacy and support further investigation.


Assuntos
Carcinoma Hepatocelular/terapia , Ablação por Cateter , Quimioembolização Terapêutica , Neoplasias Hepáticas/terapia , Idoso , Idoso de 80 Anos ou mais , Camptotecina/administração & dosagem , Camptotecina/análogos & derivados , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/cirurgia , Terapia Combinada , Doxorrubicina/administração & dosagem , Epirubicina/administração & dosagem , Feminino , Humanos , Óleo Iodado/administração & dosagem , Irinotecano , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/cirurgia , Masculino , Pessoa de Meia-Idade , Mitomicina/administração & dosagem , Taxa de Sobrevida , Resultado do Tratamento
17.
In Vivo ; 20(6A): 765-7, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17203764

RESUMO

BACKGROUND: Radiofrequency ablation (RFA) is an advanced, minimally invasive technique used to treat several types of neoplasm. Its application in the treatment of lung tumors has received great interest. PATIENTS AND METHODS: Fifty-four patients with 10 unresectable primary lung tumors and 83 lung metastases from various solid tumors were treated with percutaneous RFA. RESULTS: The procedure was performed under CT scan guidance and general anaesthesia. The rate of complete necrosis of the treated neoplasms was 95%, while the most frequent complication was pneumothorax, requiring pleural drainage in 12% of sessions. CT scan and MRI with gadolinium have shown to be accurate and useful in assessing the therapeutic efficacy of lung RFA. CONCLUSION: Lung RFA is a very promising technique, minimally invasive and well-tolerated in the majority of patients; further investigation is required in order to define the optimal role of lung RFA in the multidisciplinary therapy of lung malignancies.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/cirurgia , Ablação por Cateter/métodos , Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/cirurgia , Pulmão/cirurgia , Carcinoma Pulmonar de Células não Pequenas/patologia , Ablação por Cateter/efeitos adversos , Humanos , Pneumotórax/etiologia , Complicações Pós-Operatórias , Radiografia Intervencionista , Tomografia Computadorizada por Raios X , Resultado do Tratamento
18.
AJR Am J Roentgenol ; 183(2): 361-8, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15269026

RESUMO

OBJECTIVE: Radiofrequency thermal ablation is a minimally invasive treatment widely used for treatment of liver neoplasms and has also been tested on other types of tumor. Few studies have been published regarding the use of radiofrequency thermal ablation in the treatment of lung neoplasms. This study was performed to evaluate the technical feasibility, the safety, and the efficacy of lung radiofrequency thermal ablation. SUBJECTS AND METHODS: Between February 2002 and March 2003, 18 subjects with unresectable lung neoplasms, four of whom had primary neoplasms and 14 of whom had metastatic neoplasms, underwent lung radiofrequency ablation. The technique was performed percutaneously using a monopolar cooled-tip electrode needle under CT guidance with the patient under general anesthesia. Patients had no more than three nodules with a total diameter of 10 cm and no evidence of extrathoracic disease. A total of 40 nodules were treated in 24 therapeutic sessions. After treatment, patients underwent follow-up every 3 months by CT and nuclear MRI with gadolinium for a median time of 8 months (range, 2-14 months). RESULTS: No evidence of local relapse was discovered in 94.4% of subjects. The treatment was safe and well tolerated. Complications encountered included massive pneumothorax, which occurred in one subject, requiring pleural drainage. Other complications were moderate pneumothorax (also requiring pleural drainage), cough, fever, slight dyspnea, and pain, but these complications were short in duration and successfully treated. CONCLUSION: Radiofrequency thermal ablation is a promising technique in the treatment of patients with lung neoplasms and has been found to be both safe and technically feasible.


Assuntos
Ablação por Cateter , Neoplasias Pulmonares/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Meios de Contraste , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Radiografia Intervencionista , Tomografia Computadorizada por Raios X , Resultado do Tratamento
19.
Oncol Rep ; 10(5): 1189-93, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12883679

RESUMO

Substantial experimental data suggest that tumour progression is associated with angiogenesis and that increase in microvessel density (MVD) is associated with increase in mast cells density (MCD). Dog mast cell tumour (MCT) is common in dog with an incidence much higher than that found in human and in both species several common biological and clinical characteristics have been demonstrated. To evaluate the role of angiogenesis in progression of this tumour and to correlate MVD and MCD, in this study a series of 78 MCT was investigated. Serial sections obtained from biopsy specimens were processed with toluidine blue staining, specific for MC identification, and by immunohistochemistry using a polyclonal antibody anti factor VIII-related antigen (FVIII-RA), used as an endothelial marker, and MVD and MCD were determined. Results showed that MVD was significantly higher in poorly differentiated (G3) MCTs than in intermediate (G2) and well differentiated (G1) MCTs and that MCD and MVD were significantly correlated in G3, but not in G1 and G2 subgroups. These data indicate that angiogenesis and MCD are significantly correlated in MCTs progression.


Assuntos
Leucemia de Mastócitos/patologia , Mastócitos/patologia , Neovascularização Patológica , Animais , Vasos Sanguíneos/patologia , Diferenciação Celular , Corantes/farmacologia , Progressão da Doença , Cães , Endotélio Vascular/metabolismo , Humanos , Imuno-Histoquímica , Microcirculação , Cloreto de Tolônio/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...